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ABBREVIATION LIST 
CI: Cardiac index 
CO: Cardiac output 
NO: Nitric oxide 
NYHA: New York Heart Association 
PAH: Pulmonary arterial hypertension  
mPAP: Mean pulmonary arterial pressure  
PCWP: Pulmonary capillary wedge pressure 
PVRi: Indexed pulmonary vascular resistance  
RAP: Right atrial pressure 
PaO2: Partial pressure of arterial oxygen 
SI: Systolic index 
SpO2: Pulse arterial oxygen saturation 
SvO2: Mixed venous oxygen saturation 
TPRi: Indexed total pulmonary resistance 
6MWD: 6-minute walk distance 
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ABSTRACT  
 
 
Rationale Anesthetic management and follow-up of well-characterized 
patients with pulmonary arterial hypertension (PAH) presenting for non-
cardiothoracic non-obstetric surgery has rarely been described.  
Methods We reviewed details of consecutive patients and perioperative 
complications from January 2000 to December 2007. Repeat procedures 
in duplicate patients were excluded. Longer-term outcomes included New 
York Heart Association (NYHA) functional class; 6-minute walk 
distance (6MWD) and invasive hemodynamics. 
Main results Twenty-eight patients were identified having major (57%) 
or minor surgery under general (GA) (50%) and regional anesthesia (RA). 
At the time of surgery, 75% patients were in NYHA functional class I-II. 
Perioperative deaths occurred in 7%. Perioperative complications, all 
related to pulmonary hypertension (PH), occurred in 29% of all patients 
and in 17% with no deaths in scheduled procedures. In emergencies (n=4), 
perioperative complication and death rates were higher (100% and 50% 
respectively, p<0.005). Risk factors for complications were higher 
emergency surgery (p<0.001), major surgery (p=0.008), and long 
operative time (193 vs. 112 minutes, p=0.003). No significant clinical or 
hemodynamic deterioration was seen in survivors at 3-6 or 12 month 
post-operative follow-up.  
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 5 
Conclusions Despite optimal management in this mostly non-severe PH 
population, perioperative complications were common, although 
survivors remained stable at 6 months. Emergency procedures, major 
surgery and long operations were associated with increased risk.  
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INTRODUCTION  
Pulmonary hypertension (PH) is defined by mean resting pulmonary artery pressure 
(mPAP) greater than 25 mmHg with pulmonary capillary wedge pressure (PCWP) 
less than 15 mmHg (1). Pulmonary arterial hypertension (PAH) defines a subgroup 
characterized by vascular cell proliferation and remodeling of small resistance 
pulmonary arteries that causes elevated pulmonary vascular resistance, ultimately 
leading to right heart failure and death (1-3). PAH is classified into idiopathic, 
heritable PAH and those associated with conditions such as connective tissue diseases, 
portal hypertension and HIV infection amongst others (4). Survival remains poor with 
a 15% mortality rate at one year despite modern treatment (5), however there are 
increasing therapies available. Although PAH remains a rare disease, the most recent 
prevalence has increased compared to previous eras, at 15 per million in France (6).  
Reflecting this increasing global health burden, patients are likely to present 
not only to PH referral units but also to non-specialist centers for emergency and non-
emergency surgery. Patients with PH present one of the highest risk groups of patients 
undergoing both cardiac (7) and non-cardiac surgery (8-11), despite advances in 
perioperative monitoring and treatment. Potentially fatal complications relate to the 
consequences of right-sided circulatory failure which may be precipitated by reduced 
right ventricular contractility, excessive volume-loading or causes of further right 
ventricular pressure overload. A common mode of death appears to be minor 
stimulation resulting in tachycardia or increased pulmonary vascular resistance (PVR), 
followed by refractory hypotension, hypoxia and ultimately cardiovascular collapse 
(12, 13) due to a downwards spiral of worsening right ventricular function (14). 
Perioperative increases in PVR may be precipitated by hypoxia (15), hypercapnia (16), 
high airway plateau pressure due to the effects of positive-pressure mechanical 
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 7 
ventilation (17), atelectasis or may follow acute pulmonary embolism (18). Such PH 
complications including death may occur up to a week post-operatively (19, 20), or 
even later namely following delivery for Caesarean section (21, 22). Perioperative 
measures may be undertaken to prevent rapid hemodynamic deterioration in the 
setting of right ventricular failure. These include the use of pulmonary vasodilator 
therapies to minimize right ventricular afterload (19, 23, 24), avoiding excessive fluid 
administration, maintaining appropriate systemic perfusion pressure for adequate 
coronary perfusion and enhancing contractility (25).   
There have been very few studies of well-characterized patients with PH 
undergoing non-cardiothoracic, non-obstetric surgery. Perioperative mortality and 
complication rates have been described in one previous study as 7% and 42% 
respectively (9), and 14% and 18% in a further smaller study (11). Whereas 
perioperative care is likely to vary between institutions, further to the nature of the 
surgical procedure itself, it is not clear whether other aspects of anesthetic or 
perioperative care may influence short-term outcomes in these patients. Furthermore, 
it is unclear if operative procedures have implications on longer-term PH endpoints. 
We therefore sought to describe the cohort of PH patients undergoing surgery at our 
institution, details of their perioperative management and longer-term PH outcomes. 
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METHODS  
 
Subjects 
Retrospective data were reviewed from patients referred to the French Reference 
Centre for Pulmonary Hypertension (Université Paris-Sud 11, Hôpital Antoine 
Béclère, Clamart, France) undergoing general and regional anesthesia for non-
cardiothoracic, non-obstetric surgery between 1st January 2000 and 31st December 
2007. Patients were included if diagnosis of pre-capillary PH was confirmed before 
surgery by right-heart catheterization. Patients with chronic thromboembolic 
pulmonary hypertension (CTEPH) not amendable to endarterectomy surgery were 
also included. Exclusion criteria included patients <18 years, those with PH due to 
left heart disease and those having surgery for cardiothoracic or obstetric procedures. 
All clinical characteristics at diagnosis and follow-up were stored in the Registry of 
the French Network of Pulmonary Hypertension. This registry was set up in 
agreement with French bioethics laws (French Commission Nationale de 
l'Informatique et des Libertés) and all patients gave their informed consent (6). 
 
Clinical and functional assessment 
Patient demographics, etiology of PH, clinical features and major comorbid 
conditions were recorded at the latest time-point prior to surgery and at 3-6 month and 
6-12 month evaluation following surgery. Clinical status was assessed by the 
modified New York Heart Association (NYHA) functional class (4, 26) and the non-
encouraged 6-minute walk test (6MWT), performed according to the American 
Thoracic Society recommendations (27).  
 
Hemodynamic measurements 
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 9 
Details of preoperative hemodynamic evaluation by right heart catheterization were 
recorded in all subjects according to our previously described protocol (28). 
Precapillary pulmonary hypertension was defined as mPAP ≥25 mmHg with a normal 
pulmonary capillary wedge pressure (PCWP) ≤15 mmHg. The mPAP, PCWP, right 
atrial pressure (RAP) and mixed venous oxygen saturation (SvO2) were recorded. 
Cardiac index (CI) was measured by the standard thermodilution technique. The 
indexed pulmonary vascular resistance (PVRi) were calculated as (mPAP-PCWP)/CI.  
 
Intra-operative factors  
Anesthetic and surgical charts were examined to determine the nature of the operative 
procedure, the presence of emergency surgery and operative time (from induction of 
anesthesia until extubation or end of surgery). Major surgery was defined to include 
major laparotomy, hysterectomy, mastectomy and major orthopaedic surgery, and 
minor surgery to include hernia repair, appendicectomy and extremity orthopaedic 
surgery. Regional anesthesia (RA) was defined as neuraxial blockade or other 
regional blockade. Details of venous access, intra-operative hemodynamic monitoring 
and, for procedures under GA, details of ventilator settings, average intra-operative 
fractional inspired oxygen concentration (FiO2), peak end-expiratory CO2, peak 
airway pressure (cmH2O) and the use of nitrous oxide (N2O) as a supplementary 
anesthetic agent were recorded.  
 
Perioperative complications 
Perioperative complications were defined as those occurring during surgery or in the 
28-day postoperative period. Perioperative complications related to PH were recorded 
from operative charts and medical notes. Non-PH complications were also noted. PH 
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complications with increased right ventricular (RV) afterload leading to RV failure, 
cardiogenic shock and VQ mismatch, were of varying severity, and were defined as 
follows: major PH complications were defined by the occurrence of death or severe 
acute right heart failure (clinical signs of low cardiac output and right ventricular 
failure) requiring vasopressors and/or inotropes and/or inhaled nitric oxide (NO) 
and/or additional pulmonary vasodilator therapy (intravenous epoprostenol or 
nebulized iloprost). Minor PH complications were defined as major hypoxia requiring 
an escalation in the mode of ventilation or isolated hypotension or right ventricular 
failure not requiring the use of continuous infusions of vasopressors or inotropes.  
 
Statistical analysis 
Statistical analysis was performed using Stat view version 5.0 (Abacus Concepts Inc., 
Berkley, CA, USA). Data are presented as mean ± standard deviation (SD) or median 
(range) for parametric and non-parametric data respectively. Statistical analysis was 
performed using parametric tests (Fisher exact test, paired t-test) or non-parametric 
tests (Mann–Whitney U-test for unpaired data, Wilcoxon matched pair test for paired 
data) as appropriate. Distribution of qualitative data was assessed by Pearson's Chi-
squared test with Yates' correction for continuity or Fisher-exact test as appropriate.  
Multivariate analysis was not performed because of the small number of procedures 
as compared to the number of risk factors identified in univariate analysis. A P value 
<0.05 was considered significant.  
 
 
RESULTS  
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Preoperative patient characteristics 
Twenty-eight procedures were identified in 28 individual patients with idiopathic 
PAH (n=10, 36%), associated PAH (n=10, 36%, comprising 5 portopulmonary, 3 
connective tissue disease-associated and 2 HIV PAH) and CTEPH (n=8, 28%). Mean 
age patient was 53±16 years with a female predominance (57%). At the time of 
surgery, patients were in NYHA functional class I+II (n=21, 75%) and class III (n=7, 
25%), with no patients in class IV, and 6MWD was 388±114 m. Preoperative 
hemodynamics showed mPAP of 43±12 mmHg, normal cardiac index of 3.25x±0.68 
L/min/m² and low SvO2 (66±6%). 57% of all patients were on specific PAH therapy 
(Table I). 
 
Operative characteristics  
Of 28 procedures performed, 16 were abdominal surgery (9 inguinal hernias, 
1 umbilical hernia, 2 laparoscopic cholecystectomies, 1 splenectomy, 1 open 
appendicectomy, 2 major bowel resections), 8 orthopedic procedures (of which 4 
were major hip surgery, 2 were major knee surgery), 2 mastectomies and 2 
hysterectomies. According to our definitions, 16 (57%) were major and 12 (43%) 
were minor surgical procedures. Fourteen procedures were performed under general 
anesthesia (GA) and 14 under regional anesthesia (RA). Four were emergency 
procedures, all performed under GA (hip hemiarthoplasty, bowel resection, 
laparotomy and appendicectomy). 
 
Anesthesia characteristics  
For the 14 patients that had procedures under GA, all patients received opioids and 
propofol for induction of anesthesia, and anesthesia was maintained with sevoflurane 
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(10/14), isoflurane (2/14) or desflurane (2/14). Nitrous oxide was used as a 
supplemental anesthetic agent in 4 patients and the intra-operative FiO2 was 
0.60±0.17 (Table II).  
RA consisted of neuraxial blockade in 11/28 (spinal anesthesia in 2, combined spinal-
epidural anesthesia in 9 patients) and 3 other regional blocks (supraclavicular block, 
femoral block, lumbar plexus block) were combined with sedation in all three cases. 
For patients undergoing neuraxial blockade (n=11), spinal needles were 27G in size, 
spinal doses used were sufentanil 4.8 µg (3-7.5, data available for n=9) combined 
with 0.5% heavy bupivicaine, and epidural top-ups used 2% lidocaine in all patients. 
No patients required conversion to GA. All those previously on warfarin (n=5) were 
switched to low molecular weight (LMW) heparin (prophylactic dose) pre-operatively, 
and there were no reported bleeding complications relating to the site of regional 
blockade, including in the patients on continuous intravenous epoprostenol.  
 
There was no significant age or sex difference, or 6MWD or NYHA functional class 
difference, between those having GA or RA (Table I). As compared to RA, patients 
that had procedures under GA had less severe hemodynamic impairment with a 
significantly lower mPAP (36±10 mmHg vs. 48±11mmHg, p=0.003), PVRi (7.2±2.9 
vs. 13.9±5.5 UW/m², p=0.0003) and a higher CI (3.6±0.6 vs. 2.94±0.6, p=0.009). 
Patients having RA were more likely to be on specific PAH therapy than those having 
GA (86% vs. 29%, p=0.002).  
 
Perioperative complications 
Perioperative complications relating to PH occurred in 8/28 (29%) of procedures 
(Table III). There were no reported non-PH complications. Two deaths occurred in 
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28 procedures performed (7%), due to refractory right heart failure in both cases: one 
intraoperatively and the other at day 11. In the 4 emergency procedures, perioperative 
complications relating to PH (n=4, 100%) including death (n=2, 50%) were higher 
compared to the non-emergency procedures (with 4/24 (17%) complications and no 
deaths - altogether p<0.001, Table II). More patients that had PH perioperative 
complications had undergone major surgery compared to minor surgery (8/16 (50%) 
and 0/12 (0%) respectively, p=0.008, Table II). Mortality related to major surgery 
was 2/16 (13%) compared to no deaths in patients having minor surgery. 
Most of the complications occurred during or in the first 48h following the procedure 
(7/8, 88%). Complications included 3 severe acute right heart failure (following 
which 2 patients died), 3 cases of isolated hypotension and 2 of severe hypoxemia. 
One death occurred at the time of surgery due to a refractory right heart failure 
(patient 5), and the other (patient 8) was due to ongoing PH and right ventricular 
failure at day 11 postoperatively (see Table IV).  
 
Prognostic factors 
There was no significant difference in age or PH etiology between patients who had 
or did not have perioperative complications. There was a suggestion that patients in 
NYHA I-II were less likely to have perioperative complications than those in NYHA 
III-IV preoperatively (n=17, 80% vs. n=3, 20%, respectively; p=0.14), and that 
patients with a higher preoperative 6MWD had fewer complications (411+/-99 vs. 
311+/-140m, p=0.058). However, there was no significant difference in resting pre-
operative hemodynamics between these patient groups. There was no influence of the 
use of ‘all’ PH specific therapy on complications, although no complications occurred 
in patients receiving oral therapy alone (n=9) (Table III). 
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There was a suggestion that more perioperative complications occurred in procedures 
performed under GA compared to RA (6, 75% vs. 2, 25% with GA and RA, 
respectively, p=0.12). Procedures with associated perioperative complications were 
longer than uncomplicated procedures (193 (120-420) vs. 112 (45-465 minutes, 
p=0.003). More patients with CVP or intra-arterial monitoring (3, 38%) and in whom 
cardiac output monitoring (using PAC or esophageal Doppler) (3, 38%) was used had 
complications than those without (0 and 5%, respectively) (Table II). 
 
In patients undergoing GA, there was no significant difference in FiO2 between 
patients with (0.60±0.12) or without perioperative complications (0.59±0.20), and 3 
(38%) of patients with complications were given the supplemental anesthetic agent 
nitrous oxide compared to 1 (5%) of those without complications. High peak end-tidal 
(ET) CO2 and peak airway pressure were not significantly associated with 
perioperative complications (p=0.17 and p=0.51, respectively; Table II). 
 
 
Longer-term outcomes  
When perioperative deaths had been excluded, the remaining survivors (n=26) 
showed no evidence of significant clinical or hemodynamic deterioration at 3-6 
months follow-up. At preoperative baseline, 19/26 (73%) of survivors were in NYHA 
functional class I-II compared with 22/26 (85%) at 3-6 months’ follow-up (p=0.31). 
Accordingly, 7/26 (27%) patients were in NYHA functional class III-IV before 
surgery and 4 (15%) at follow up (including one patient in NYHA class IV) (p=0.77) 
(Table V). Only 2 patients (8%) had an increase in PAH therapy over this period. 
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There was no significant worsening in 6MWD (n=17) or hemodynamics (n=11) for 
those where follow-up data were available at 3-6 months. Even for the 6 patients who 
suffered perioperative complications and survived, NYHA functional class, 6MWD 
and hemodynamic assessment were unchanged at 3- 6 months (data not shown). 
Furthermore, there was no significant deterioration in clinical status in survivors 
assessed at 6-12 months, whether perioperative complications had occurred or not 
(Figure I). 
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DISCUSSION  
In this single-centre study, we described the anesthetic management, perioperative 
complications and PH outcomes in this high-risk population undergoing non-
cardiothoracic, non-obstetric surgery. In this cohort of well-characterized patients 
with mostly mild to moderate PAH and non-operable CTEPH, overall perioperative 
mortality was 7% and the incidence of perioperative complications up to day 28 was 
29%. These are relatively high adverse event rates despite operating on mostly non-
severe patients in an experienced PH center.  
Data on complications and mortality after non-cardiothoracic, non-obstetric 
surgery in this population are rare with only two previous single-centre studies 
available. One study of 145 patients showed that perioperative mortality and 30-day 
morbidity rates were 7% and 42% respectively for patients of similar NYHA 
functional class undergoing similar surgical procedures under GA, although this study 
did not include such well-characterized patients with regard to PH classification: 
some patients had PH secondary to lung disease, and some were diagnosed using 
echocardiography without hemodynamic confirmation (9). The second is a smaller 
study of well-characterized patients with more severe PAH compared to this study 
(mPAP 53±14 mmHg, 62% NYHA III-IV) undergoing 28 surgical procedures. Of 
these, 12 were abdominal, 6 thoracic (including lung biopsies and resections but not 
endarterectomy surgery), 4 gynecological and 4 orthopedic procedures, and 79% were 
performed under GA. Most complications reported related to the surgical procedure 
itself, with only 14% of cases complicated by reversible right ventricular failure, 
although deaths occurred in 18% patients (11). The lower overall mortality in our 
study probably reflects the fact that patients had less severe disease, no thoracic 
procedures were performed, and only 50% had GA compared to this last study. 
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However, mortality/complication rates of patients in our study undergoing emergency 
or major procedures (100%/50% and 13%/50% respectively) were very high, and 
previous studies have not divided surgical procedures in this way to enable true 
comparisons. 
Previous studies have suggested that RA may be safer than GA in patients 
with PH, although this may at least partly be explained by reducing the risk imparted 
by GA. A recent series of 73 PAH obstetric deliveries suggested that GA was 
associated with a fourfold increase in maternal mortality (univariate analysis, OR 
4.37, 95% CI 1.28–16.5, p=0.02). (22). This has also been suggested in patients with 
Eisenmenger’s syndrome where of 103 non-cardiac anesthetics, perioperative 
mortality of those receiving GA was 18% compared to 5% of those undergoing RA, 
although this may well have been an indirect indicator of the increased mortality seen 
in major vs. minor surgery (24% vs. 5%, p<0.01) as more patients having GA also 
had more major surgery (29). Patients with PAH that tolerate pregnancy have a 
particularly high perioperative risk, with historical mortality of 36-50% (21, 30), 
which even in the ‘modern treatment’ era remains as high as 25% (22). Obstetric 
operative deliveries were excluded in this study for this reason. However, useful 
experience with obstetric RA is extrapolated to the non-obstetric setting.  Successful 
incremental regional blockade has been used in PAH obstetric deliveries (21) and is 
well tolerated by mothers with PH (31). RA was previously thought harmful in 
patients with PH because of the hemodynamic compromise following sympathetic 
blockade, however using a low intrathecal dose minimizes this potential drop in 
afterload, and careful incremental epidural top-ups are well tolerated. RA techniques 
have also been useful in patients with PH in general surgery [9, 10]. RA may be an 
inappropriate anesthetic technique, however, for many procedures, as well as in 
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emergencies when planned cessation of anticoagulation is not possible. In well-
selected non-emergency patients undergoing suitable procedures, however, these data 
suggest relative safety of RA compared to GA in PH.  The lack of reported bleeding 
at the site of neuraxial puncture even in patients on epoprostenol is notable, with the 
theoretical increased risk due to the anti-platelet aggregation effects of prostacyclins. 
Both deaths reported in this study followed refractory acute right heart failure, 
with one death intraoperatively and one at day 11. Most non-fatal complications 
occurred intraoperatively, and related in varying degrees to isolated right ventricular 
failure not requiring vasopressors and/or inotropes. Previous studies have showed that 
similar causes of perioperative deaths in patients undergoing non-cardiac, non-
obstetric surgery may occur suddenly (11, 20) or up to 48 hours following surgery 
(32). Obstetric PAH deaths have been reported even up to one month after delivery 
(22), and guidelines suggest that obstetric patients should be monitored for at least up 
to 72 hours post-operatively (33). In this study, we recorded perioperative 
complications related to PH and death in a 28-day post-operative period, with most 
(11/12, 92%) of the complications occurring in the first 48h. 
In this study, significant univariate predictive factors for perioperative 
complications including death were found to be emergency surgery, major surgery 
and long operative time. Increased risk was suggested by the use of GA rather than 
RA, more severe preoperative NYHA functional class, shorter 6MWD. Preoperative 
resting invasive hemodynamics were not predictive of outcome, which may reflect the 
small sample size, or perhaps indicate that exercise end-points are more sensitive in 
this setting, which bears similarities to pre-operative cardiopulmonary exercise testing 
in the general surgical population. In a prospective study of patients (including those 
<60y with cardiac disease) undergoing major abdominal surgery, pre-operative 
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anaerobic threshold (AT) predicted outcome, whereby no patients died when AT 
exceeded 11ml/min/kg, but 4.6% died when AT<11ml/min/kg (34). AT was used as it 
is independent of patient effort and occurs well below VO2max, the more usually 
recorded value in PH, where VO2max <10.4ml/min/kg has been shown to predict 
poor survival (35). It would be useful to know from future studies if AT above a 
certain threshold was also predictive of better surgical outcomes in this specific 
patient population. 
There was a suggestion that patients monitored with CO monitoring (either 
PAC or esophageal Doppler) had more complications, although these are likely to 
indicate the more complex patients. Intra-operative invasive hemodynamic 
monitoring is not without risk, with both arrhythmias and pulmonary artery 
thrombosis and rupture reported (36), although using a PAC is useful with a falling 
cardiac output and mPAP and a rising CVP as markers of acute right ventricular 
decompensation (25). The perioperative use of PAC in patients with PH is debated. 
With the background that many complications are potentially avoidable, and that 
good team-work improves outcomes, a recent study in non-cardiac surgery has shown 
that use of a standardized safety checklist reduced complications (37). 
This study has suggested that the use of GA as compared to RA was 
associated with worse outcomes. Most patients having GA were undergoing 
emergency or major surgery, known to be associated with worse outcomes  (38, 39) 
and these are likely to be major confounding factors. However, there were more 
severe patients having RA, indicated by both hemodynamics and that significantly 
more patients on specific PAH therapy had RA than GA. The use of GA may increase 
PVR through several mechanisms including increased sympathetic stimulation during 
airway instrumentation at laryngoscopy (40), effects of volatile agents (41), high 
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airway plateau pressure due to the effects of positive-pressure mechanical ventilation 
(12, 13]), hypoxia (15) and hypercapnia (16). Our data suggested more complications 
occurred in those with higher ETCO2 and peak airway pressure, although many 
confounding factors may affect these values. Anesthetic volatile agents may also 
adversely affect right ventricular preload and contractility (25), as well as afterload 
(41), although isoflurane has been used in human PAH (42). Desflurane appears to 
exert worse pulmonary vascular effects than isoflurane probably through sympathetic 
activation (43, 44). Some studies suggest that nitrous oxide as a supplemental 
anesthetic agent may increase PVR, especially in those with elevated pre-existing 
PVR (45), and it may also adversely influence endothelial function (46). An increase 
in adverse cardiovascular events following major surgery has been observed (47), 
possibly also through adverse pulmonary vascular effects of increased 
sympathomimetic stimulation (48, 49) or hypoxia (50), and a study addressing these 
questions is ongoing (51).  
Despite the fact that patients having complications had worse functional 
capacity, longer-term PH outcomes (including 6MWD, NYHA and hemodynamics) at 
3-6 months were not adversely influenced by having had surgery. For those where 
data were available at 6-12 months, NYHA functional class was similarly unchanged. 
The occurrence of perioperative complications did not adversely influence these 
outcomes. This is likely to relate to appropriate patient selection and perioperative 
management of complications. These data suggest that the risk of procedures was 
associated with perioperative complications and the possibility of occurrence of 
complications related to PH may not influence the evolution of the disease after the 
perioperative period, suggesting that essential surgical procedures may not always be 
contraindicated in patients with stable PH.  
Page 20 of 64European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 21 
In addition to the confounding influence by the surgical disease severity and 
the type of surgery performed, limitations to this study include its retrospective nature. 
However, selection bias was minimized by examining consecutive cases. A further 
limitation relates to the small sample size preventing the use of multivariate analysis. 
The potential influence of GA, in addition to the surgical type, on PH complications 
would require much larger patient numbers. This retrospective study does, however, 
emphasize several issues, which will be addressed further in an ongoing prospective 
multicenter international registry.    
In conclusion, this study has shown that the incidence of complications 
associated with non-cardiothoracic, non-obstetric surgery remain high even in patients 
with mild to moderate PAH, especially in those having longer operations, emergency 
and major procedures, and those performed under GA, with most occurring within the 
first 48 hours following surgery. The suggestion that more patients with worse 
functional status had more complications indicates that assessment of exercise 
tolerance should form part of preoperative examination. Regional anesthesia may be a 
safe approach in appropriately selected patients. Perioperative deaths occurred, 
especially following emergency procedures, but the mortality rate remains lower than 
following obstetric operative deliveries in patients with PH (22, 30). Long-term 
follow up after surgery suggested no disease deterioration in surviving patients. Non-
emergency procedures may not necessarily be contraindicated in appropriately 
selected PH patients if managed in an experienced PH center in the pre, peri and post-
operative periods. 
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Table I: Pre-operative patient factors in patients having general 
and/or regional anesthesia  
 
 All patients 
 
GA (or 
GA+RA) 
RA alone p value 
Surgical cases 
 
28 14 (50%) 14  
Age at time of 
surgery (yrs) 
 
53 +/- 16 53.3 +/- 15 52.5 +/- 17 0.89 
Sex (% female) 16 (57%) 8 (57%) 8 (57%) 1  
PH type 
Idiopathic PAH 
Associated PAH** 
CTEPH 
 
 
10 (36%) 
10 (36%) 
8 (28%) 
 
2 (14%) 
8 (57%) 
4 (29%) 
 
8 (57%) 
2 (14%) 
4 (29%) 
 
0.03  
Specific Therapy 
 
No 
Yes 
 
Bosentan* 
Sildenafil* 
Epoprostenol* 
Other prostanoids 
Calcium channel 
blockers 
* includes patients on 
combination Rx 
  
 
12 (43%) 
16 (57%) 
 
10 
2 
5 
2 
1 
 
 
 
10 (71%) 
4 (29%) 
 
8 
1 
1 
1 
0 
 
 
2 (14%) 
12 (86%) 
 
2 
1 
4 
1 
1 
 
 
0.002 
  
 
  
NYHA (%) 
Class I+II 
Class III 
 
 
 
21 (75%) 
7 (25%) 
 
 
11 (79%) 
3 (21%) 
 
 
10 (71%) 
4 (29%) 
 
 
0.66 
 
6MWD (m) 
 
388 +/- 114 394 +/- 94 383 +/- 133 0.81  
Hemodynamics: 
 
 
mPAP, mmHg 
RAP, mmHg 
PCWP, mmHg 
 
 
 
43±12 
6±4 
8.8±3 
 
 
 
36±11 
5±3 
8.5±3 
 
 
 
49±9.5 
7±4 
8.9±3 
 
 
 
0.003 
0.08 
0.77 
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CI, L/min/m² 
SVI, ml/m² 
PVRi, UW/m² 
SvO2, % 
3.25±0.68 
42±10 
11.1±5.7 
66±6 
3.60±0.62 
44±9 
7.1±3.2 
70±2 
2.93±0.58 
39±11 
14.5±5.0 
64±7 
0.009 
0.33 
<0.001 
0.04 
 
GA general anesthesia, RA regional anesthesia. *Treatments included 
those on combination therapy. ‘Other prostanoids’ included beraprost 
and iloprost. Data expressed as mean ± SD. Means were compared using 
unpaired t-tests. **Comprising 5 Portopulmonary PH, 3 Connective 
tissue disease-PAH and 2 HIV-PAH patients 
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Table II: Major perioperative complications during GA: Operative 
factors  
 
Major perioperative complications were defined by the occurrence of 
death or severe acute RVF (right ventricular failure) with clinical signs 
 All patients Patients with 
perioperative 
PH 
complications 
(8) 
 
Patients 
without 
perioperative 
PH 
complications 
(20) 
p value 
Emergency 
surgery 
 
4/28 (14%) 4 (100%) 0 <0.001 
 
Major surgery 
Minor surgery 
16 
12 
8 (100%) 
0 
8 (40%) 
12 (60%) 
0.008  
GA  
RA  
14 
14 
6 (75%) 
2 (25%) 
8 (40%) 
12 (60%) 
0.12  
Operative time 
(min) 
133 (45-
465) 
193 (120-420) 112 (45-465) 
 
0.003 
Monitoring Standard 
monitoring 
with: 
+CVP/arteri
al line 
+CO (PAC 
or 
esophageal 
Doppler) 
 
 
 
3 
  
3  
 
 
 
0 
 
1 
 
 
 
 
 
 
General anesthesia  (n=14)    
 
FiO2  
 
0.60 +/- 0.17 0.60 +/- 0.12 0.59 +/- 0.20 0.90 
Use of anaesthetic 
agent nitrous oxide 
(N2O)/GA total 
 
4 3 1  
Peak ETCO2 
(mmHg)  36.1 +/- 5.4 38.6 +/- 6.7 34.1 +/- 3.5 0.17 
 
Peak airway 
pressure 
(cmH2O)  
20.8 +/- 6.8 22.4 +/- 8.8 19.6 +/- 5.0 0.51 
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of low cardiac output requiring vasopressors and/or inotropes and/or 
inhaled nitric oxide (NO) and/or additional pulmonary vasodilator 
therapy (intravenous epoprostenol or nebulized iloprost).  
All patients had standard monitoring, which includes ECG, non-invasive 
BP and oximetry. CVP is central venous pressure and art line is invasive 
arterial blood pressure monitoring (if used, most patients had both). 
Cardiac output (CO) includes monitoring with pulmonary artery 
catheterization (PAC) or the use of esophageal Doppler.  
Major surgery included laparotomy, hysterectomy, mastectomy and 
major orthopaedic surgery. Minor surgery included hernia repair and 
extremity orthopaedic surgery.  
Data expressed as mean +/-SD for parametric or median (min-max) for 
non-parametric data. Comparisons were made using unpaired t-test or 
Mann Whitney tests for parametric/non-parametric data respectively. 
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Table III: Perioperative PH complications: Patient factors  
 All patients With 
perioperative 
PH 
complications 
up to D28 
 
Without 
perioperative 
PH 
complications 
up to D28 
p value 
Patients 
 
28 8 (29%) 20 (71%)  
Age (years) 
 
53 +/- 16 52 +/- 18  54 +/- 15 0.76  
PH type ** 
 
Idiopathic PAH 
Associated PAH 
CTEPH 
 
 
 
10 (36%) 
10 (36%) 
8 (28%) 
 
 
3 (37%) 
4 (50%) 
1 (13%) 
 
 
7 (35%) 
6 (30%) 
7 (35%) 
 
 
 
0.44  
 
Specific 
Therapy 
 
No 
Yes 
 
Oral Rx only 
 
Bosentan* 
Sildenafil* 
Epoprostenol* 
Other 
prostanoids 
CCBs 
* includes 
combination Rx  
 
 
 
12 (43%) 
16 (57%) 
 
9 
 
10 
2 
5 
 
2 
1 
 
 
 
 
4 (50%) 
4 (50%) 
 
0  
 
0 
1 
3 
 
1 
0 
 
 
 
8 (40%) 
12 (60%) 
 
9  
 
10 
1 
2 
 
1 
1 
 
 
 
 
0.69  
 
 
 
NYHA 
Class I+II 
Class III 
 
 
 
21 (75%) 
7 (25%) 
 
 
 
4 (50%) 
4 (50%) 
 
 
17 (80%) 
3 (20%) 
 
 
 0.14 
6MWD m 
 
388 +/- 114 311 +/- 140 411 +/- 99 0.058  
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*The treatments included those on combination therapy. ‘Other 
prostanoids’ were beraprost and iloprost. **Associated PAH consisted of 
5 Portopulmonary PH, 3 Connective tissue disease-PAH and 2 HIV-PAH 
patients
Hemodynamics 
 
mPAP, mmHg 
RAP, mmHg 
PCWP, mmHg 
CI, L/min/m² 
SVI, ml/m² 
PVRi, UW/m² 
SvO2, % (n=18) 
 
 
 
43 +/- 12 
6.3 +/- 4 
9 +/- 3 
3.25 +/- 0.68 
42 +/- 10 
11.1 +/- 5.7 
66 +/- 6 
 
 
44 +/- 13 
6.2 +/- 4 
9.3 +- 4 
3.28 +/- 0.52 
38 +/- 8 
10.0 +/- 4.6 
71 +/- 6 
 
 
43 +/- 12 
6.3 +/- 4 
8.6 +/- 3 
3.24 +/- 0.75 
43 +/- 10 
11.5 +/- 6.1 
64 +/- 6 
 
 
0.77 
0.93 
0.59 
0.89 
0.25 
0.60 
0.05  
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Table IV: PH-related perioperative complications  
 
 
Patient PH type, age, NYHA, 
therapy 
Surgery 
Eme
rgen
cy 
Anesthesia 
Operati
ve time  
(minute
s) 
Complicatio
n details 
(including  
death) 
Timing of 
onset of 
complication 
1 Associated, 83y 
NYHA III, 
No therapy 
Hemiarthopla
sty Y GA+RA 120 Hypotension Intra-operative 
2 Associated, 44y 
NYHA II 
No therapy 
Total hip 
replacement 
(THR) 
N GA+CSE 210 Hypoxia Intra-operative 
3 Idiopathic, 44y 
NYHA II, 
Flolan 
Knee 
arthrodesis N RA (CSE) 180 
Tachycardia 
and 
hypotension 
D1 post-
operatively 
4 Idiopathic, 63y 
NYHA III 
Flolan+ 
sildenafil 
ORIF 
humerus N 
RA 
(supraclavi
cular 
block) 
120 Hypoxia Intra-operative 
5 Associated, 43y 
NYHA II 
Flolan 
Bowel 
resection Y GA 180 
Refractory 
RVF; died at 
time of 
surgery 
Intra-operative 
6 Associated, 61y 
NYHA II, Laparotomy Y GA 150 
Hypotension, 
arrhythmias 
Following 
intubation 
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Beraprost 
7 CTEPH, 55y 
NYHA III, 
No therapy 
Pancreatecto
my N GA 420 Acute RVF 
Following 
intubation 
8 Idiopathic, 20y 
NYHA IV 
None; flolan + 
bosentan later 
Appendix Y GA n/a 
Refractory 
RVF, death 
D11 
Intra-operative 
and post-
operative 
 
Major perioperative complications were defined by the occurrence of death or severe acute RVF (right ventricular failure) with clinical signs of 
low cardiac output requiring vasopressors and/or inotropes and/or inhaled nitric oxide (NO) and/or additional pulmonary vasodilator therapy 
(intravenous epoprostenol or nebulized iloprost). Minor PH complications were defined as major hypoxia requiring an escalation in the mode of 
ventilation or isolated hypotension or right ventricular failure not requiring the use of continuous infusions of vasopressors or inotropes.
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Table V: Follow-up data (for paired survivors only, n=26)  
. 
 
 
All survivors (n=26) 
 
Baseline 3-6 months P 
Clinical status  
NYHA I-II 
NYHA III+IV 
 
Increase in therapy  
 
6MWD (m) (n=17) 
 
Hemodynamics (n=11 for 
paired values) 
 
RAP, mmHg 
 
PVRi, UW/m²  
 
mPAP, mmHg  
 
CI, L/min/m² 
 
 
19 (73%) 
7 (27%) 
 
 
 
382 +/- 112 
 
 
 
 
7 +/- 4 
 
14.5 +/- 5.60 
 
49 +/- 11 
 
2.94 +/-0.57 
 
 
22 (85%) 
4 (15%) 
 
2 (8%) 
 
387 +/- 124 
 
 
 
 
10 +/- 4 
 
12.02 +/- 6.59 
 
46 +/- 12 
 
3.54+/-1.18 
 
 
0.31 
 
 
 
 
0.77 
 
 
 
 
0.06 
 
0.04 
 
0.49 
 
0.05 
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PCWP, mmHg 
 
SvO2, % (n=5) 
 
8 +/- 3 
 
63 +/- 9 
9 +/- 3 
 
59 +/- 11 
0.31 
 
0.33 
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387x305mm (150 x 150 DPI)  
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